Acquired sideroblastic anaemia induced by a copper-chelating agent.
Acquired sideroblastic anaemia may be related to drugs and other chemicals that inhibit the activity of mitochondrial enzymes involved in haem synthesis. We report a case of secondary acquired sideroblastic anaemia following administration of triethylene tetramine dihydrochloride (trientine), a second-line copper-chelating agent used in the treatment of Wilson's disease. The anaemia improved after dose reduction of trientine. The mechanism of induction of sideroblastic anaemia in this case is unclear, but trientine does not appear to alter the function of two key mitochondrial haem enzymes, and may instead act directly on mitochondrial iron metabolism.
Perry
A R
AR
Department of Haematology, King's College Hospital, London, UK.
Pagliuca
A
A
Fitzsimons
E J
EJ
Mufti
G J
GJ
Williams
R
R
D000293:Adolescent; D000756:Anemia, Sideroblastic / Q000139:chemically induced*; D002614:Chelating Agents / Q000009:adverse effects*; D003300:Copper / Q000378:metabolism*; D005260:Female; D006527:Hepatolenticular Degeneration / Q000188:drug therapy; D006801:Humans; D014266:Trientine / Q000009:adverse effects*
D002614:Chelating Agents; D003300:Copper; D014266:Trientine